Anuh Pharma

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE489G01022
  • NSEID: ANUHPHR
  • BSEID: 506260
INR
79.74
-0.07 (-0.09%)
BSENSE

Feb 06

BSE+NSE Vol: 41.48 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Fredun Pharma
Sakar Healthcare
Wanbury
Lincoln Pharma.
Anuh Pharma
Kopran
Sigachi Indust.
Themis Medicare
Anlon Healthcare
Accent Microcell
Remus Pharma.

Why is Anuh Pharma Ltd ?

1
Poor long term growth as Net Sales has grown by an annual rate of 13.69% and Operating profit at 7.18% over the last 5 years
2
Flat results in Dec 25
  • ROCE(HY) Lowest at 15.90%
  • CASH AND CASH EQUIVALENTS(HY) Lowest at Rs 2.15 cr
3
Despite the size of the company, domestic mutual funds hold only 0% of the company
  • Domestic mutual funds have capability to do in-depth on-the-ground research on companies- their small stake may signify either they are not comfortable at the price or the business
4
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 7.71% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -21.55% returns
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Anuh Pharma for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Anuh Pharma
-21.55%
-0.54
40.24%
Sensex
7.07%
0.61
11.53%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
13.69%
EBIT Growth (5y)
7.18%
EBIT to Interest (avg)
42.53
Debt to EBITDA (avg)
0.36
Net Debt to Equity (avg)
-0.04
Sales to Capital Employed (avg)
2.06
Tax Ratio
24.70%
Dividend Payout Ratio
15.87%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
19.97%
ROE (avg)
14.83%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
21
Industry P/E
32
Price to Book Value
2.44
EV to EBIT
17.35
EV to EBITDA
14.13
EV to Capital Employed
2.50
EV to Sales
1.08
PEG Ratio
NA
Dividend Yield
1.88%
ROCE (Latest)
14.43%
ROE (Latest)
11.84%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company
NET SALES(9M)

At Rs 569.54 cr has Grown at 22.91%

PBT LESS OI(Q)

At Rs 13.72 cr has Grown at 22.7% (vs previous 4Q average

PAT(Q)

Highest at Rs 13.45 cr.

EPS(Q)

Highest at Rs 1.34

-4What is not working for the Company
ROCE(HY)

Lowest at 15.90%

CASH AND CASH EQUIVALENTS(HY)

Lowest at Rs 2.15 cr

Loading Valuation Snapshot...

Here's what is working for Anuh Pharma

Net Sales - Nine Monthly
At Rs 569.54 cr has Grown at 22.91%
Year on Year (YoY)
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 13.72 cr has Grown at 22.7% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 11.18 Cr
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
Highest at Rs 13.45 cr.
in the last five quarters
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 13.45 cr has Grown at 39.0% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 9.68 Cr
MOJO Watch
Near term PAT trend is positive

PAT (Rs Cr)

Earnings per Share (EPS) - Quarterly
Highest at Rs 1.34
in the last five quarters
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (Rs)

Here's what is not working for Anuh Pharma

Cash and Cash Equivalents - Half Yearly
Lowest at Rs 2.15 cr
in the last six half yearly periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents